In a last-minute breakthrough just days before a scheduled jury trial, Moderna has agreed to a settlement worth up to $2.25 billion with Arbutus Biopharma and Roivant’s subsidiary, Genevant Sciences. This deal resolves a long-standing legal battle over lipid nanoparticle (LNP) technology—the critical delivery system used to transport mRNA into cells in Moderna’s blockbuster vaccines.
Under the terms of the settlement, Moderna will issue an upfront payment of $950 million in the third quarter of 2026. An additional $1.3 billion in potential payouts is currently being challenged in a federal circuit court. Crucially, this lump-sum arrangement exempts Moderna from paying future royalties on its mRNA vaccine sales. By reaching this agreement, Moderna effectively avoids a “worst-case scenario” that could have included a $5 billion liability and ongoing royalty burdens.
Market analysts view the settlement as a strategic victory for Moderna, as it provides financial certainty and protects the company’s balance sheet. With this legal overhang removed, the firm can now shift its full focus to upcoming growth drivers, including anticipated oncology data readouts later this year. Moderna’s stock price surged 9% following the announcement, signaling investor relief and confidence in the company’s near-term fiscal stability.